SYS-6002

靶向治疗已成为尿路上皮癌治疗的新选择，其中Nectin 4（也称为PVRL4）作为理想治疗靶点备受关注。Nectin 4是一种位于细胞表面的蛋白质，在维持细胞间连接和信号传导中发挥重要作用。研究发现，它在约97%的尿路上皮癌中高度表达，而在正常组织中表达较低，能够精准识别并结合表达该蛋白的肿瘤细胞，进而激活免疫系统或携带毒性物质特异性地杀伤癌细胞，最大限度减少对正常组织的损伤，这种特性使其成为抗癌药物研发的理想靶点。 患者因“肉眼血尿”辗转多家医院后被确诊为左肾盂尿路上皮癌（cT4NxM1 IV期），此时肿瘤已转移至肾上腺、腹膜后淋巴结，并因压迫引发肾积水等并发症。由于手术获益有限且术后复发风险高，多家医院均建议采取内科治疗。在得知我院正开展一项“评价SYS6002（Nectin 4靶向药）联合SG001在晚期尿路上皮癌及其他晚期实体瘤受试者中安全性、耐受性、药代动力学特征及初步疗效的开放、多中心II期临床研究（SYS6002-002）”后，患者前来咨询，经过筛选顺利入组。 今年3月，患者接受了首次治疗。4个周期后，肿瘤即得到有效控制；治疗8个周期后，肿瘤明显缩小。整个治疗过程中，未出现严重不适症状，目前仍在持续获益中。   //   目前，针对Nectin 4的抗体药物偶联物（ADC）已在多项临床研究中显示出良好疗效，为晚期尿路上皮癌患者提供了新的治疗选择。 科室介绍 黑色素瘤、泌尿软组织肿瘤内科（肿瘤免疫治疗中心）是福建省最早成立的以黑色素瘤、泌尿软组织肿瘤为学科特色的肿瘤内科亚专业。科室编制床位32张，科室共有2名正高级职称专家、2名副高级职称专家和7名中级职称专家。作为福建医科大学与福州大学的博士、硕士培养点，科室现有1位博士生导师和3位硕士生导师。在学科带头人陈誉副院长带领下，经过多年的不懈努力，科室在黑色素瘤、泌尿及软组织肿瘤内科的治疗和研究方面取得了显著的成果。陈誉主任医师、陈玲主任医师和林晶副主任医师作为主要执笔者，参与了多部国家级指南的制定。 科室注重临床与科研的结合，多位骨干成员参与和主持了十余项国家级和省级科研项目，包括中青年重大项目、联合创新课题等。相关研究成果多次在ASCO、ESMO等国际知名会议上进行报道和展示，并发表了60余篇SCI文章，其中包括在《JAMA Oncology》等刊物上发表的高质量论文。2024年，围绕黑色素瘤核心内容申报的《肿瘤精准免疫治疗体系的构建和研究》项目，荣获福建省抗癌协会科技进步一等奖、福建省科技进步二等奖。 自建科起，科室承担了70余项临床研究，跻身国内该领域第二，推动了5个创新药物的中国上市，赢得业界高度认可。在积极开展常规治疗手段的同时，科室还注重在新技术方面的探索，为患者提供先进的诊疗措施。目前，科室开展了“人工智能皮肤检查灯辅助皮肤疾病诊断技术”和“溶瘤病毒皮下注射治疗晚期黑色素瘤技术”等新技术，荣获“福建省肿瘤医院医疗技术创新奖”。这些新技术的引入使得科室能够不断提升诊疗水平，为患者提供更先进、更个性化的治疗方案，帮助患者获得更好的治疗效果和生活质量。科室将继续关注和应用最新的医疗技术，不断推动科技创新，为患者提供更好的医疗服务。 专家简介 陈誉 福建省肿瘤医院副院长，博士、主任医师、博士研究生导师，福建省高层次人才，主要从事黑色素瘤、泌尿、软组织肿瘤以及消化系统肿瘤的内科治疗，聚焦新型靶向以及免疫治疗的临床应用、转化基础研究以及疾病全周期管理，在创新药物临床研究领域具有丰富的经验，对肿瘤免疫治疗以及抗肿瘤药物治疗相关器官损伤，有很深的理解及临床诊治经验。 林晶 I期临床试验病房及肿瘤内科十九病区临时负责人，副主任医师，硕士生导师，福建省高层次人才，主要从事黑色素瘤、泌尿肿瘤、软组织肿瘤以及消化系统肿瘤的内科治疗工作，在创新药物临床研究领域具有丰富的经验。 黑色素瘤、泌尿软组织肿瘤内科（肿瘤免疫治疗中心）微信号 黑色素瘤、泌尿软组织肿瘤内科（肿瘤免疫治疗中心）/供稿 陈丽珠 林中樵/文 林晶/审 编排 | 黄梦蝶 林夕梦

Plus, news about Syncona, Ventus Therapeutics, Roche, Disc Medicine, Atai Life Sciences, Lexeo Therapeutics, Novartis, Vivace Therapeutics, Kura Oncology, Corbus and J&J: 💼 Neuphoria Therapeutics’ social anxiety drug fails Phase 3: The biotech is discontinuing BNC210 after the drug did not meet the primary endpoint in a public speaking challenge in the AFFIRM-1 trial. Neuphoria is now conducting a strategic review of its business and assessing what to do with BNC210 in post-traumatic stress disorder. It’s still partnered with Merck on a Phase 2 trial in Alzheimer’s disease. The company’s shares $NEUP were down about 68% the morning after it disclosed the results. — Jaimy Lee 🧠 Minerva Neurosciences’ up to $200M PIPE: The company gets $80 million upfront as it advances its experimental schizophrenia treatment through a confirmatory Phase 3 trial. It then plans to resubmit roluperidone to the FDA. Vivo Capital led the financing. The FDA has twice declined to approve the drug. Its stock price $NERV soared 275% on Tuesday morning after disclosing the private placement. — Jaimy Lee 📋 Syncona details plans to recoup £250M for shareholders: Earlier this year, the British life sciences investment firm announced it won’t hit its 2032 goals of £5 billion in assets, launching three companies each year, and having a portfolio of at least 20 startups. It may sell mature portfolio companies, update the board or establish a new private fund. The firm still plans to invest in early-stage companies. “We are committed to ensuring shareholders benefit from the potential returns available as markets stabilize,” Syncona Investment Management CEO Chris Hollowood said in a statement. — Jaimy Lee 🧪 Ventus Therapeutics, Roche ink licensing deal: Roche’s Genentech could pay more than $460 million plus royalties to use Ventus’ AI and machine learning platform to develop small molecules. The companies didn’t disclose the targets, though they described them as “challenging” and in “major disease areas.” — Jaimy Lee 💰 Disc Medicine raised a total of $250 million in its stock sale, above the $220 million it set out to raise. Atai Life Sciences also had an upsized offering, selling $149.5 million in shares. It had intended to sell about $130 million . The same goes for Lexeo Therapeutics , which raised $153.8 million , up from its plans to sell $135 million in shares. — Jaimy Lee ↔️ #ESMO25: One step back, one step forward for a rare cancer: Novartis told Endpoints News it is ending enrollment in a Phase 1 trial of IAG933 in advanced mesothelioma and other solid tumors, citing “tolerability and anti-tumor activity.” Meanwhile, Vivace Therapeutics reported promising Phase 1/2 results for its candidate, VT3989, in refractory mesothelioma. The drug achieved a 32% overall response rate and disease control rate of 86%. — Ayisha Sharma 🔬 #ESMO25: Kura Oncology details new vision for an old drug class: The company reported that its farnesyl transferase inhibitor darlifarnib combined with Exelixis’ Cabometyx, resulted in response rates of 33% to 50% across doses in kidney cancer patients. That included patients who previously progressed on Cabometyx. Kura’s vision is to use darlifarnib in combination with other targeted drugs as a way to overcome resistance that eventually develops to the treatments. — Lei Lei Wu 💊 #ESMO25: Corbus, Johnson & Johnson’s showdown in head and neck cancer: Corbus drew eyes with Phase 1/2 data for its nectin-4 targeting antibody-drug conjugate, which is called CRB-701. The drug achieved response rates ranging from about 33% to 48% in head and neck squamous cell carcinoma, depending on the dose. J&J is also eyeing HNSCC with Rybrevant. The bispecific antibody produced an overall response rate of 45% in a cohort of Phase 1b/2 patients with HPV-unrelated recurrent or metastatic disease, according to the presentation. — Ayisha Sharma